Dr Josep Tabernero currently serves as the Head of the Medical Oncology Department at the Vall d’Hebron University Hospital, the Director of the Vall d’Hebron Institute of Oncology (VHIO) and Professor of Medicine at UVic-UCC.

His research centers on molecular targeted therapies, targeting specific oncoproteins, and novel immunotherapies, advancing and accelerating more effective personalized cancer medicines for patients displaying genetic lesions or pathway dysregulation. Dr Tabernero’s expertise includes predictive markers of response to anti-cancer therapies and innovative preclinical models (patient-derived xenografts and organoids) for studying tumor development. He has also (co) authored nearly 600 peer-reviewed papers with an H-Index of 122 and serves on the Editorial Boards of various top tier journals including Cancer Discovery, Clinical Cancer Research, and Nature Reviews Clinical Oncology.

Dr Tabernero’s contributions as the former President of the European Society for Medical Oncology - ESMO (2018-2019) and a member of esteemed cancer research associations like AACR and ASCO drive advancements in oncology globally. Dr Tabernero is also Chair of Cancer Core Europe (from October 2023) and member of the Board of Directors of the Organisation of European Cancer Institutes (OECI) and has been a member of the Educational and Scientific Committees of ESMO, ASCO, AACR, AACR/NCI/EORTC, ASCO Gastrointestinal, TAT and ESMO-GI meetings.

At VHIO we are keen to both share our expertise as well as benefit from the experience of many others through international collaboration. We are particularly proud to be a member of the WIN consortium -  a combined tour de force behind original research projects led by private and academic institutions in cross-border and multidisciplinary unison.